Literature DB >> 16961431

Primary care treatment of attention-deficit/hyperactivity disorder.

Larry Culpepper1.   

Abstract

Primary care physicians should consider the role of families of patients with attention-deficit/ hyperactivity disorder (ADHD) not just in terms of their genetic relationship but also in terms of the role family can play in assisting in the treatment and management of the disorder. When first encountering a new case of ADHD, primary care physicians should confirm the diagnosis, identify comorbidities and other primary disorders, and develop a comprehensive assessment of the patient with ADHD that includes consideration of family-related influences. Management of multiple medical, mental health, and psychosocial problems over time will often be ineffective if ADHD is not adequately managed. The most effective management should be multimodal, with patients benefiting from caring professionals with special expertise in the treatment of ADHD as well as the primary care physician. Successful management of ADHD begins with establishing a therapeutic alliance with the patient and affected family that includes patient and family education and agreement on patient-specific goals, treatment, follow-up, and monitoring. As pharmacotherapy controls the core symptoms of ADHD, the primary care physician and treatment team should discuss with the patient other supportive interventions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16961431

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

1.  Managing ADHD in children, adolescents, and adults with comorbid anxiety in primary care.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.

Authors:  Daniel Y Lin; Christopher J Kratochvil; Wen Xu; Ling Jin; Deborah N D'Souza; William Kielbasa; Albert J Allen
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-05       Impact factor: 2.576

3.  A randomized, double-blind, placebo-controlled phase 2 study of α4β2 agonist ABT-894 in adults with ADHD.

Authors:  Earle E Bain; Weining Robieson; Yili Pritchett; Tushar Garimella; Walid Abi-Saab; George Apostol; James J McGough; Mario D Saltarelli
Journal:  Neuropsychopharmacology       Date:  2012-10-03       Impact factor: 7.853

Review 4.  Diagnosis and Treatment of Attention Deficit Hyperactivity Disorder During Adolescence in the Primary Care Setting: A Concise Review.

Authors:  Khyati Brahmbhatt; Donald M Hilty; Mina Hah; Jaesu Han; Kathy Angkustsiri; Julie B Schweitzer
Journal:  J Adolesc Health       Date:  2016-05-18       Impact factor: 5.012

Review 5.  Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults.

Authors:  Christopher Gibbins; Margaret Weiss
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

6.  Do parents of children with attention-deficit/hyperactivity disorder (ADHD) receive adequate information about the disorder and its treatments? A qualitative investigation.

Authors:  Rana Ahmed; Jacqueline M Borst; Cheng Wei Yong; Parisa Aslani
Journal:  Patient Prefer Adherence       Date:  2014-05-08       Impact factor: 2.711

7.  Can adolescents with eating disorders be treated in primary care? A retrospective clinical cohort study.

Authors:  Jocelyn Lebow; Angela Mattke; Cassandra Narr; Paige Partain; Renee Breland; Janna R Gewirtz O'Brien; Jennifer Geske; Marcie Billings; Matthew M Clark; Robert M Jacobson; Sean Phelan; Cynthia Harbeck-Weber; Daniel Le Grange; Leslie Sim
Journal:  J Eat Disord       Date:  2021-04-23

8.  A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).

Authors:  Gerhardt M Pohl; David L Van Brunt; Wenyu Ye; William W Stoops; Joseph A Johnston
Journal:  BMC Health Serv Res       Date:  2009-06-08       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.